Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
Saved in:
| Title: | Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. |
|---|---|
| Authors: | Ison MG; Bethesda, Maryland, USA., Papi A; Pulmonary Division, University of Ferrara, St. Anna University Hospital, Ferrara, Italy., Athan E; Barwon Health, University Hospital Geelong, Geelong, Australia.; Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, Australia., Feldman RG; Senior Clinical Trials, Inc, Laguna Hills, California, USA., Langley JM; Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada., Lee DG; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Leroux-Roels I; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium., Martinon-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.; Genetics, Vaccines, Infectious Diseases, and Pediatrics Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain., Schwarz TF; Institute of Laboratory Medicine and Vaccination Center, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany., van Zyl-Smit RN; Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa., Verheust C; GSK, Wavre, Belgium., Dezutter N; GSK, Wavre, Belgium., Gruselle O; GSK, Wavre, Belgium., Fissette L; GSK, Wavre, Belgium., David MP; GSK, Wavre, Belgium., Kostanyan L; GSK, Wavre, Belgium., Hulstrøm V; GSK, Wavre, Belgium., Olivier A; GSK, Wavre, Belgium., Van der Wielen M; GSK, Wavre, Belgium., Descamps D; GSK, Wavre, Belgium. |
| Corporate Authors: | AReSVi-006 Study Group |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1732-1744. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38253338 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ison+MG%22">Ison MG</searchLink>; Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Papi+A%22">Papi A</searchLink>; Pulmonary Division, University of Ferrara, St. Anna University Hospital, Ferrara, Italy.<br /><searchLink fieldCode="AU" term="%22Athan+E%22">Athan E</searchLink>; Barwon Health, University Hospital Geelong, Geelong, Australia.; Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, Australia.<br /><searchLink fieldCode="AU" term="%22Feldman+RG%22">Feldman RG</searchLink>; Senior Clinical Trials, Inc, Laguna Hills, California, USA.<br /><searchLink fieldCode="AU" term="%22Langley+JM%22">Langley JM</searchLink>; Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada.<br /><searchLink fieldCode="AU" term="%22Lee+DG%22">Lee DG</searchLink>; Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Leroux-Roels+I%22">Leroux-Roels I</searchLink>; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.<br /><searchLink fieldCode="AU" term="%22Martinon-Torres+F%22">Martinon-Torres F</searchLink>; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.; Genetics, Vaccines, Infectious Diseases, and Pediatrics Research Group, Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.; Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Schwarz+TF%22">Schwarz TF</searchLink>; Institute of Laboratory Medicine and Vaccination Center, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22van+Zyl-Smit+RN%22">van Zyl-Smit RN</searchLink>; Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Verheust+C%22">Verheust C</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Dezutter+N%22">Dezutter N</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Gruselle+O%22">Gruselle O</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Fissette+L%22">Fissette L</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22David+MP%22">David MP</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Kostanyan+L%22">Kostanyan L</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Hulstrøm+V%22">Hulstrøm V</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Olivier+A%22">Olivier A</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+der+Wielen+M%22">Van der Wielen M</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Descamps+D%22">Descamps D</searchLink>; GSK, Wavre, Belgium. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22AReSVi-006+Study+Group%22">AReSVi-006 Study Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229203213%22">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</searchLink> [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1732-1744. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9203213 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6591 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210584838%22">10584838 </searchLink><i>NLM ISO Abbreviation: </i>Clin Infect Dis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38253338 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/cid/ciae010 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1732 Titles: – TitleFull: Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ison MG – PersonEntity: Name: NameFull: Papi A – PersonEntity: Name: NameFull: Athan E – PersonEntity: Name: NameFull: Feldman RG – PersonEntity: Name: NameFull: Langley JM – PersonEntity: Name: NameFull: Lee DG – PersonEntity: Name: NameFull: Leroux-Roels I – PersonEntity: Name: NameFull: Martinon-Torres F – PersonEntity: Name: NameFull: Schwarz TF – PersonEntity: Name: NameFull: van Zyl-Smit RN – PersonEntity: Name: NameFull: Verheust C – PersonEntity: Name: NameFull: Dezutter N – PersonEntity: Name: NameFull: Gruselle O – PersonEntity: Name: NameFull: Fissette L – PersonEntity: Name: NameFull: David MP – PersonEntity: Name: NameFull: Kostanyan L – PersonEntity: Name: NameFull: Hulstrøm V – PersonEntity: Name: NameFull: Olivier A – PersonEntity: Name: NameFull: Van der Wielen M – PersonEntity: Name: NameFull: Descamps D IsPartOfRelationships: – BibEntity: Dates: – D: 14 M: 06 Text: 2024 Jun 14 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1537-6591 Numbering: – Type: volume Value: 78 – Type: issue Value: 6 Titles: – TitleFull: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Type: main |
| ResultId | 1 |